Palmitoleic Acid.

Palmitoleic acid is made endogenously from palmitic acid by the insertion of a double bond at the delta-9 position by stearoyl-CoA desaturase 1. The ratio between the two in blood is used as an index of that enzyme's activity. The two are chemically one desaturation step apart, which is why a circulating palmitoleic acid level reflects internal lipid metabolism as much as it reflects what was eaten.

Stearoyl-CoA desaturase 1 makes oleic acid from stearic acid and palmitoleic acid from palmitic acid. The two products come from one enzyme, so substrate availability shifts the balance between them. Oleic acid is by far the more abundant of the two in human tissue and in the diet. This is enzymology, not an interaction to act on.

Polyunsaturated fatty acids downregulate the transcription of the delta-9 desaturase, which is well characterised in the lipid metabolism literature. A high linoleic acid intake therefore tends to lower the internally produced share of palmitoleic acid. The effect is on gene expression rather than direct enzyme blockade. It is one reason a blood palmitoleic acid level cannot be read as a simple intake marker.

Erythrocyte membrane fatty acids exist in a fixed total, so raising the EPA and DHA share changes the proportional representation of other fatty acids including 16:1n-7. A profile shift in a membrane is a compositional change, not an outcome. Anyone tracking a palmitoleic acid percentage while also taking fish oil should expect the denominator to move.

Any unsaturated fatty acid preparation is vulnerable to peroxidation on exposure to oxygen, light and heat. Mixed tocopherols are added to the oil phase to slow that in soft gels and liquid oils. This protects the ingredient rather than the person. The pairing is formulation convention across the whole oil category.

Astaxanthin dissolves in the oil phase and contributes to slowing peroxidation there. It is commonly co-packed with marine and plant oils for that reason as well as for its own claimed effects. Whether the combination does anything additional in a person has not been separated in trials.

Lecithin emulsifies oil into finer droplets, which increases the surface area available to pancreatic lipase. This is standard lipid delivery formulation and applies to any oil. Palmitoleic acid is also found natively in phosphatidylcholine fractions, so the two overlap compositionally as well as functionally.

Vitamin D3 is absorbed better when taken with fat, which is why it is routinely supplied in oil-filled soft gels. A palmitoleic acid oil provides that vehicle. Nothing about this is specific to 16:1n-7, but it is a genuine reason the two are co-packed.

Medium-chain fatty acids are absorbed largely into portal blood without requiring chylomicron packaging, while long-chain fatty acids like 16:1n-7 need micelle formation and lymphatic transport. Blending them does not make the long-chain portion behave like the medium-chain portion. MCT is often used as a carrier oil, where its role is dilution and mouthfeel.

Both ingredients get positioned around blood sugar handling in marketing, which is the only thing connecting them. There is no shared pathway, no measured interaction and no combination trial. Listed here so the absence is on the record rather than left for someone to assume a link exists.